
There are over a hundred cannabinoids in cannabis and around ten of them are sold to consumers. They act at different receptors, in different directions, and their evidence bases differ enormously, from three regulatory-grade trials at one end to zero human studies at the other.
Three things separate these compounds, and none of them is a flavour preference. Read them before you read any comparison, because they decide what a claim is worth.
CBD does not activate CB1 at all. THC is a partial agonist at it. CBC prefers CB2. The target decides the effect.
Two cannabinoids can meet the same receptor and pull opposite ways. THCV blocks CB1 at low doses and activates it at high ones.
From three regulatory-grade trials at one end to zero human studies at the other. Most minor cannabinoid data is in vitro or rodent.
Most comparison content treats cannabinoids as a menu of wellness options. They are not that. They act at different receptors, in different directions, and their evidence bases differ enormously.
No comparison matches that search.
Every claim on this table is sourced on the individual pages. Binding affinity numbers for the minor cannabinoids are genuinely inconsistent between labs, so assay context matters.
Important context: Human trials showing effects for CBD used 100 to 1,600 mg a day. Consumer products typically deliver 10 to 50 mg. No trial evidence supports scaling those findings down.
Receptor figures are in vitro and vary between laboratories. The evidence bar counts human trials, not cell studies.
Understanding the biosynthesis makes the table easier to read. Cannabis makes one precursor, CBGA. Three enzymes compete for it. THCA synthase produces THCA. CBDA synthase produces CBDA. CBCA synthase produces CBCA. Whatever CBGA is left becomes CBG.
Heat and time then strip a carbon dioxide group from each acid, giving THC, CBD, CBC and CBG.
CBN has no synthase; it is what THC becomes when it oxidises. Delta-8 THC is barely present in natural hemp and is generally manufactured by acid conversion from CBD.
Built from a shorter starting molecule, it produces CBDV and THCV. That branch is genetically segregated, which is why varin content is rare in ordinary hemp.
Each one changes what a claim on the pages ahead is actually worth.
Human trials showing effects for CBD used 100 to 1,600 mg a day. Consumer products typically deliver 10 to 50 mg. No trial evidence supports scaling those findings down.
CBC, CBDa and THCa have essentially no controlled human data at all. Binding affinity numbers are also genuinely inconsistent between labs, and any single figure quoted without its assay context is misleading.
Two studies designed specifically to test whether cannabis terpenes modulate cannabinoid receptor activity found they do not. A 2024 scoping review concluded there is limited evidence for it as a stable and predictable phenomenon.
As of September 2026 the 2018 Farm Bill governs: hemp means no more than 0.3 percent delta-9 THC by dry weight, and hemp derivatives are excluded from the Controlled Substances Act.
The test changes to total THC including THCA, cannabinoids synthesized or manufactured outside the plant are excluded, and finished products are capped at 0.4 mg total THC per container.
A one-month delay had passed the Senate but not the House as of 1 September 2026, and FDA had not published the cannabinoid lists the new rules depend on, more than six months past its deadline.
Every page in this hub carries a review date for that reason.
The legal position in the United States has one date running through it, and it falls this November.
We grow our own hemp, run our own extraction and publish a third-party certificate of analysis for every batch, so we can tell you the measured cannabinoid content tied to the batch code on the bottle.
A company selling these compounds has an obvious incentive to overstate them. We would rather publish the trials that failed alongside the ones that worked.
Each comparison page carries its own reference list. These are the primary sources underpinning the master table.